GlassScriptPhysician profile
Sandesh K Joshi
NPI 1861704710
$4,782.89
in general payments reported to CMS, 2019-2025
21 companies · $2,251 in 2025
The $2,251 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.17 · 2020: $53.58 · 2021: $273 · 2022: $291 · 2023: $1,245 · 2024: $657 · 2025: $2,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,128 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,127.78 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $778.13 | 2023-2025 | |
| Vifor Pharma, INC. | $659.00 | 2020-2025 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $442.75 | 2023-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $416.12 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $329.25 | 2020-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $321.08 | 2021-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $239.42 | 2025 | |
| Amgen INC. | $215.58 | 2022-2025 | Tavneos, Krystexxa |
| Scpharmaceuticals INC. | $200.89 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.48 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $168.73 | 2023 | Acthar |
| Aurinia Pharma U.S., INC. | $153.40 | 2022-2025 | Lupkynis |
| Novo Nordisk INC | $148.13 | 2022-2025 | Ozempic, Wegovy |
| Ardelyx, INC. | $118.74 | 2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $115.22 | 2023-2025 | Ultomiris |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $103.07 | 2023-2025 | Benlysta, Shingrix |
| Ani Pharmaceuticals, INC. | $73.15 | 2023-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $71.20 | 2023-2025 | Tarpeyo |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Philips North America LLC | $21.77 | 2023 | |
| Horizon Therapeutics Plc | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandesh Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.